A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Stapuldencel-T (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms VIABLE
- Sponsors SOTIO
- 01 Feb 2019 Planned primary completion date changed from 16 Dec 2018 to 16 Dec 2019.
- 05 Nov 2018 Planned primary completion date changed from 1 Sep 2018 to 16 Dec 2018.
- 31 Aug 2018 Biomarkers information updated